Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CAR-T

- PMLiVE

Am I wrong to be apprehensive about gene therapy?

Is the introduction of gene therapy going to be smooth sailing? Origin's Strategic Solutions Director, Su Smith, shares her thoughts.

Bedrock Healthcare Communications

- PMLiVE

Gene therapy market access Q&A

Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy Catapult gives his personal view on how to get the new therapies to patients

- PMLiVE

Novartis builds case for SMA gene therapy as FDA verdict looms

One shot therapy provided rapid improvement in motor function

- PMLiVE

Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

Expects to file with the FDA next year

- PMLiVE

Gracell Bio developing faster, cheaper CAR-T production

Manufacturing can be cut from two weeks to one day

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

Sangamo surges on data for haemophilia A gene therapy

After recent setbacks, news lifts shares

- PMLiVE

CMS proposes coverage scheme for CAR-T therapies

Proposal says it would improve access to CAR-Ts

- PMLiVE

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

- PMLiVE

UniQure edges closer to haemophilia B gene therapy OK

The candidate could free patients from regulator injections of FIX products

- PMLiVE

J&J bolsters gene therapy unit with $100m MeiraGTx deal

Licenses two inherited retinal disorder candidates

- PMLiVE

Novartis buys CellforCure to bolster cell, gene therapy

Move would make existing partner an in-house capability

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links